Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gisslinger

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Annals of Hematology|July 28, 2001
Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myelomaN Worel, H Greinix, J Ackermann, et al.
Leukemia|January 9, 2015
Allelic imbalance in CALR somatic mutagenesisA S Harutyunyan, R Jäger, D Chen, et al.
Annals of Hematology|February 1, 1994
Granulocytic sarcoma of the prostate as the first manifestation of a late relapse of acute myelogenous leukemiaF Thalhammer, H Gisslinger, A Chott, et al.
Clinical and Experimental Rheumatology|July 1, 1991
Efficacy of cyclosporin A in systemic sclerosisH Gisslinger, O C Burghuber, G Stacher, et al.
Annals of Hematology|June 1, 1993
Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL)R Scherrer, K Geissler, P A Kyrle, et al.
Oncology|January 1, 1985
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseasesH Ludwig, A Cortelezzi, B G Van Camp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2003
Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic featuresH Kaufmann, J Ackermann, H Greinix, et al.
European Journal of Haematology|January 27, 2007
Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging SystemV Sagaster, H Kaufmann, V Odelga, et al.
Leukemia|August 11, 2007
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myelomaD Heintel, N Zojer, M Schreder, et al.
Leukemia|September 24, 2004
Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myelomaH Kaufmann, J Ackermann, C Baldia, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Annals of Hematology|July 28, 2001
Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myelomaN Worel, H Greinix, J Ackermann, et al.
Leukemia|January 9, 2015
Allelic imbalance in CALR somatic mutagenesisA S Harutyunyan, R Jäger, D Chen, et al.
Annals of Hematology|February 1, 1994
Granulocytic sarcoma of the prostate as the first manifestation of a late relapse of acute myelogenous leukemiaF Thalhammer, H Gisslinger, A Chott, et al.
Clinical and Experimental Rheumatology|July 1, 1991
Efficacy of cyclosporin A in systemic sclerosisH Gisslinger, O C Burghuber, G Stacher, et al.
Annals of Hematology|June 1, 1993
Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL)R Scherrer, K Geissler, P A Kyrle, et al.
Oncology|January 1, 1985
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseasesH Ludwig, A Cortelezzi, B G Van Camp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2003
Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic featuresH Kaufmann, J Ackermann, H Greinix, et al.
European Journal of Haematology|January 27, 2007
Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging SystemV Sagaster, H Kaufmann, V Odelga, et al.
Leukemia|August 11, 2007
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myelomaD Heintel, N Zojer, M Schreder, et al.
Leukemia|September 24, 2004
Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myelomaH Kaufmann, J Ackermann, C Baldia, et al.
Pageof 10